A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes

Next Previous
Trial Profile

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2010

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 02 Dec 2010 Results published in NEJM.
    • 01 Jul 2008 Primary endpoint met. Results presented at the American Society of Clinical Oncology (ASCO) 2008.
    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top